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Dengue virus infections are an emerging global
threat. Severe dengue infection is manifested as
dengue hemorrhagic fever and dengue shock syn-
drome, both of which can be fatal complications.
Factors predisposing to complicated disease and
pathogenesis of severe infections are discussed. Using
immunohistochemistry, immuno¯uorescence, ¯ow
cytometry, and ELISA techniques, we studied the
cellular targets of dengue virus infection, at both the
clinical (in vivo) and the laboratory (in vitro) level.
Resident skin dendritic cells are targets of dengue
virus infection as demonstrated in a skin biopsy from
a dengue vaccine recipient. We show that factors
in¯uencing infection of monocytes/macrophages
and dendritic cells are different. Immature dendritic
cells were found to be the cells most permissive for
dengue infection and maybe early targets for infec-
tion. Immature dendritic cells exposed to dengue
virus produce TNF-a protein. Some of these imma-
ture dendritic cells undergo TNF-a mediated matur-
ation as a consequence of exposure to the dengue
virus. Key words: hemorrhagic virus infects APC. Journal
of Investigative Dermatology Symposium Proceedings
6:219±224, 2001
D
isease attributable to the dengue virus (DV) is a
major global health burden with an estimated
50 million or more infections occurring each year
(WHO, 2000). The emergence of dengue as a
worldwide public health problem over the past 50 y
is, in part, due to increased urbanization and ecologic disruptions,
peridomestic mosquito breeding grounds, increased air travel, and
the gradual reintroduction of the vector into many areas once
considered vector-free (Gubler and Dengue, 1997). Dengue illness
can be caused by any one of four antigenically distinct serotypes
(DEN 1±4) and unfortunately, no long-term cross-protection is
provided by any given serotype. The principal vector, Aedes
aegypti, is now ®rmly re-established in South and Central America,
and the Gulfcoast states of the U.S.A., which heightens the threat
of potential epidemic dengue transmission within the U.S.A.
(Gubler, 1997). Four such epidemics have been described in Texas
in the past 20 y (DEN-1 in 1980 and 1986, and DEN-2 in 1995
and 1997).
DV causes a febrile illness with myriad clinical manifestations
which range from benign to life threatening. The incubation period
averages 2±7 d and symptoms range from a mild febrile illness with
rash and muscle and joint pains (``break-bone fever'') to a severe
disease called dengue hemorrhagic fever (DHF). Dengue is a
reportable disease and speci®c case de®nitions are provided by the
World Health Organization to facilitate diagnosis and treatment
(WHO, 1997). Provisional diagnosis of DHF requires (i) fever, (ii)
hemorrhagic manifestations, (iii) thrombocytopenia, and (iv)
objective evidence of increased capillary permeability. Dengue
shock syndrome (DSS) is de®ned as all four of the above plus
hypotension. Without appropriate ¯uid resuscitation the outcome
of DHF/DSS can be fatal.
The reason for such extremes in the clinical manifestation of
dengue infection is still a matter of debate, but there are several
possible explanations. Dengue is the prototype virus for the
concept of immune-mediated enhancement of infection. This
compelling hypothesis, ®rst advanced 30 y ago, attributes severe
disease (DHF/DSS) to a process called ``antibody-mediated
enhancement'', or ADE (Halstead, 1970). This theory is based
on the epidemiologic observation that almost all DHF/DSS
cases occur in individuals experiencing a second DV infection
(Halstead, 1970), and on an in vitro ``serologic'' phenomenon
originally reported 40 y ago describing the paradoxical enhance-
ment of infectivity of arboviruses at subneutralizing concentra-
tions of antibody (Hawkes, 1964). The ADE theory proposes
that pre-existing antibodies (to a prior heterotypic DV infec-
tion) actually facilitate infection of monocyte/macrophage cells
via their abundant Fc receptors. The fact that multiple dengue
serotypes usually circulate in areas where DHF occurs, allowing
for sequential infections, provides further support of the ADE
mechanism. If ADE allows for the in vivo ampli®cation of the
virus, which then causes severe dengue disease, one might
expect to see higher viremia in severe dengue infections. In
fact, recent data published from Thailand provide this in vivo
correlate showing higher virus titres (one log higher) in severe
dengue infection (Vaughn et al, 2000). Another major hypoth-
esis invokes viral virulence mechanisms. Several recent reviews
conclude that a combination of host immunologic and viral
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factors are involved in the pathogenesis of DHF (Rothman and
Ennis, 1999; Vaughn et al, 2000).
The target cell for DV has been described previously as a
mononuclear phagocyte, monocyte, or macrophage. Although
some investigators have proposed that DV replication occurs in skin
(Taweechaisupspong et al, 1996a), the initial target cell had not
been identi®ed. We have recently shown that human skin DC
(Langerhans cells) are targets for DV infection (Wu et al, 2000). We
observed that immature human dendritic cells (DC), in contrast to
other leukocytes, were preferentially permissive for dengue infec-
tion. Unlike monocytes/macrophages, DV infection was not
enhanced by dengue speci®c antibody; however, exposure of
human DC to DV induces TNF-a-mediated maturation of the
DC.
MATERIALS AND METHODS
Cytokine-driven blood derived DC and macrophages Blood DC
were generated from PBMC using IL-4 and GM-CSF to drive the
CD14+ population to differentiate into DC (Wu et al, 2000). Brie¯y,
positively selected CD14+ monocytes were isolated from PBMC using a
MACS cell isolation column (Miltenyi Biotech, Auburn, CA) according
to manufacturer's guidelines. Monocytes were seeded in plastic ¯asks at a
density of 1±2 3 106 cells per ml of culture media prepared as follows:
RPMI-1640 (Quality Biologics, Gaithersburg, MD) supplemented with
10%±15% heat-inactivated fetal calf serum (PAA Laboratories, Parker
Ford PA), 100 U penicillin per ml, 100 mg streptomycin per ml, and
2 mM L-glutamine (BioWhittaker, Walkersville, MD) containing
1000 U per ml each of recombinant human IL-4 (R&D Systems,
Minneapolis, MN) and GM-CSF (Immunex, Seattle, WA). Cytokines
were replenished on alternate days and cells were used on day 6 or 7 as
immature DC. To produce mature DC, culture media was supplemented
with macrophage conditioned media (MCM) and the cells were kept in
culture for an additional 2±3 d. The appropriate phenotype of immature
and mature DC was con®rmed by ¯ow cytometry prior to each
experiment (all DC were CD14±, CD1a+, HLA-DR+, CD80+, CD86+
only mature DC were CD83+ and DC-LAMP+). For generation of
macrophages, PBMC were adhered to IgG-coated ¯asks in culture media
containing 10% heat-inactivated normal human serum and 500 U per ml
of recombinant human GM-CSF. After removal of nonadherent cells,
macrophages were maintained in culture for 6±7 d.
DV infection Cells were exposed to DV at different MOI (ratio of
virus:cell) for 2 h at 37°C, washed twice to remove cell free virus, and
cultured at 1±2 3 106 cells per ml. Unless otherwise speci®ed, cells were
harvested on day 2 after infection and experiments were performed with
the prototype strain New Guinea C (NGC), which belongs to DV
serotype 2. Cell free supernatants were collected after overnight culture
of DV exposed DC for the measurement of cytokines (TNF-a, IL-12,
and type I interferons). Cytokines were measured using commercially
available kits according to the manufacturer's recommendations (TNF- a
and IL-12 R&D, and type I interferon endogen). Select experiments
were performed with primary patient strains of DV from serotypes 1, 2,
and 4. These primary DV strains were isolated from patient sera. Three
IgG1 mouse anti-DV monoclonal antibodies (MoAb) (3H5, 2H2, and
7E11) were used to detect DV antigen on infected cells (Henchal et al,
1985). 3H5 is speci®c for DV serotype-2 envelope glycoprotein, 2H2
reacts with an envelope complex epitope conserved on serotypes 1±4,
and 7E11 binds to a nonstructural protein 1, which is conserved among
DV serotypes (generously donated by R. Putnak). Supernatants from the
infected cell cultures collected for a DV plaque assay were centrifuged at
250 g for 10 min at 4°C and DV plaque forming units per ml were
measured on BHK21 cells as previously described (Morens et al, 1985).
For ADE studies, DV (NGC) was preincubated for 2 h at 37°C, at MOI
of 0.2 and 2.0, with serial dilutions of dengue immune plasma. Immature
blood DC or K562 cells (a transformed continuous cell line permissive
for dengue infection and susceptible to antibody-dependent
enhancement) were exposed to pretreated virus for 2 h at 37°C and
placed into fresh media for 24±48 h. The percentage of cells expressing
DV-2 antigen was determined using MoAb 3H5 by both
immuno¯uorescence and ¯ow cytometry.
Immuno¯uorescence assay (IFA) For immuno¯uroescence
staining, cells were spotted in triplicate on 24 well HTC Super Cured
IFA slides (Erie Scienti®c, Portsmouth, NH) as previously described (Wu
et al, 1995). The slides were air-dried and then ®xed in cold 100%
acetone at ±20°C for 10 min. Primary anti-DV MoAb were detected
with ¯uorescein isothiocyanate (FITC)-conjugated goat antimouse
secondary antibody (Cappel/Organon Teknika, Durham, NC).
Preparations were then counterstained with 0.05% Evans blue.
Flow cytometry The DC phenotype was routinely assessed using a
panel of directly conjugated MoAb and a FACScan ¯ow cytometer
(Becton Dickinson, San Jose, CA). The MoAb used were against HLA-
DR, CD80, CD86, CD3, CD14, CD16 (FcgRI), CD20 (Becton
Dickinson, San Jose, CA); CD83 (Immunotech, Miami, FL); CD1a, and
CD32 (Fc g RII), CD64 (Fcg RIII) (PharMingen, San Diego, CA), and
isotype matched controls. For the intracellular detection of DV antigens,
cells were ®xed with 4% paraformaldehyde and permeabilized with 0.5%
saponin. In some experiments, directly conjugated 2H2-FITC was used.
Alternatively, indirect staining with MoAb 3H5 was detected with an
FITC-conjugated goat antimouse antibody.
Human clinical trial vaccinee The volunteer participated in an IRB
approved, phase I clinical trial to study a live attenuated tetravalent DV
vaccine. The vaccine was composed of all four serotypes of DV that had
undergone serial passages in primary dog kidney (PDK) cells and fetal
rhesus lung cells: DEN-1 (45AZ5 PDK20), DEN-2 (S16803 PDK50),
DEN-3 (CH53489 PDK20), and DEN-4 (341750 PDK20). The vaccine
was given subcutaneously and consisted of 1.8 3 106, 3.0 3 106,
3 3 104, and 2.3 3 105 pfu of each serotype, respectively.
RESULTS
Hemorrhagic rash in primary dengue infection
Approximately 50% of patients with dengue fever and most with
DHF/DSS experience some skin manifestation of disease. Figure 1
depicts the hemorrhagic nature of a dengue rash in a young child in
South-east Asia. The classic distribution is on the extremities and
can be petechial or purpuric in nature. Frequently, a more subtle
skin manifestation of dengue is an erythematous rash described as
``islands of normal skin surrounded by con¯uence of rash''.
Patients with either dengue fever or DHF/DSS can experience
hemorrhagic complications; more severe disease is associated with
clinically signi®cant hemorrhage and vascular leak syndrome. Most
dengue infections in the U.S.A. are imported and inability to
Figure 1. Primary dengue infection in a Thai infant demonstrates
the distribution and hemorrhagic nature of the dengue rash.
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recognize the signs of infection can place the individual at
unnecessary risk. The rashes associated with primary dengue
infection can be biphasic, occuring early in the infection and
after defervescence. The critical stage in severe dengue infection is
around the time of defervescence. In the setting of DHF/DSS,
hemorrhagic complications often begin as the temperature falls to
normal and without appropriate ¯uid management, hypotension,
shock, and death may follow. The WHO case de®nition of DHF/
DSS is part of the Global Strategy to reduce the morbidity and
mortality due to dengue infection. Current practice, in endemic
areas, is to hospitalize patients with disease for observation and, in
fact, a liberal admission policy has led to improved outcomes
(Vaughn et al, 2000).
DC are preferential targets of dengue infection Historically,
the macrophage has played a prominent role in dengue
pathogenesis (Halstead et al, 1977). Many investigators have
demonstrated the infectibility of mononuclear phagocytes, and in
particular the enhancement of that infection in the presence of
immune antibodies. We set out to determine if DC could be
infected with DV, since the disease is transmitted through the skin
(a relatively DC-rich site) and previous work has suggested that
dengue replication may occur within the skin. Initial experiments
compared infection rates between monocytes/macrophages and
DC derived from the same donors. Figure 2(a, b) shows that
approximately 10 times as many DC were infected when compared
with macrophages after exposure to DV (MOI = 0.2). This
relationship held true even when the cells were exposed to
higher amounts of virus (MOI 2); with maximal infection of
macrophages and DC being 5% and 35%, respectively. As early
experiments involved ``mixed'' DC populations containing both
immature and mature DC, we next asked whether either
subpopulation of DC was more susceptible to infection. Separate
populations of immature and mature DC were compared for
infectivity and for evidence of productive infection, as determined
by expression of dengue antigens, 3H5 (surface glycoprotein) and
7E11 (nonstructural protein indicating active replication),
respectively, using ¯ow cytometry. Figure 2(c) is a representative
experiment (one of four) showing that immature DC were
preferentially infected when compared with mature DC from the
same donor under identical conditions. Experiments performed
with primary isolates from DEN-1, -2, and -4 serotypes
demonstrated similar results with expression of DV antigens
restricted to the immature DC population, as shown in a
representative experiment in Fig 2(d).
Infection of FcR-bearing immature DC is unaffected by
immune serum The next set of experiments set out to
determine if the ADE phenomenon could be observed in
immature DC, as these cells are reported to express Fcg receptors,
the putative receptor involved in ADE. Figure 3(a) is a
comparison of K562 cells (a human neoplastic cell line
standardized for in vitro DV-antibody dependent enhancement
assays) and DC that were exposed to virus that had been incubated
with immune serum. Antibody titration experiments were
performed. At the lowest dilutions tested, the immune serum
Figure 2. Immuno¯uorescence and ¯ow cytometry of DV-infected DC. Immuno¯uorescence staining of (a) macrophages and (b) DC infected
with DEN-2 (NGC) virus at an MOI of 0.2 with MoAb 3H5 and an FITC-conjugated secondary antibody (green). Evan's blue was used as a
counterstain (red). (c) Flow cytometry of DEN-2 (NGC) exposed immature and mature DC populations stained with 3H5 (structural protein) and
7E11 (nonstructural protein indicative of replication) MoAb. (d) Flow cytometry of immature DC exposed to three different serotypes of primary
dengue isolates. Dengue antigens were detected on day 2. Scale bar: 20 mm.
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neutralized DV infection of both K562 cells and DC; however,
when the serum was diluted to 1:2560, the number of K562 cells
expressing DV antigen increased from 5% to 40%. In contrast, there
was no enhancement of the infection of DC at any serum dilution
tested. Interestingly, both the immature DC and the K562 cells
expressed similar levels of Fcg receptors. Figure 3(b) shows the
mean percentage (mean 6 SD) of cells binding to anti-FcR
antibodies (CD16, CD32, and CD64) on both DC and K562 cells
using by ¯ow cytometry. We found that 69% 6 18.5% of
immature DC and 30% 6 13.5% of K562 cells expressed Fcg RII
in a minimum of three experiments. Furthermore, the mean
¯uorescence intensity (MFI 6 SD) of the FcRII expression on
immature DC was greater than that of the K562 controls
(125.4 6 64 and 38.3 6 24.2, respectively). Much lower levels
of Fcg RI and Fcg RIII were found on both of these cell types.
Similar to K562 cells, primary monocytes under test conditions for
enhancement, increased DV antigen expression from 4% to 24% in
the presence of immune serum (data not shown).
Exposure of DC to DV induces TNF-a-mediated
maturation The following experiments describe the
consequences of DV and DC interactions. Our previous work
had suggested a maturational effect on immature DC upon
exposure to DV with induction and expression of intracellular
DC-LAMP (Wu et al, 2000), a DC-speci®c maturational marker
(de Saint-Vis et al, 1998). We and colleagues (Ho et al, 2001) have
found that DC secrete TNF-a protein after exposure to DV. We
hypothesized that as TNF-a itself can mature DC ± this may, in
part, be a mechanism for maturation. Figure 4(a) shows the
concentration-dependent induction of TNF-a measured as
secreted protein in culture supernatants after overnight incubation
(18±24 h) in one representative experiment of four. As shown in
Fig 4(b), in the presence of a speci®c monoclonal antibody that
blocks both soluble and membrane-bound TNF-a induction of
CD83 was markedly inhibited, whereas the control antibody (IgG1)
allowed maturation. Heat killed DV did not infect the DC, nor did
it induce any appreciable maturation (not shown). We looked for,
but did not ®nd, IL-12 or other soluble mediators of DC
maturation that logically might be induced in the setting of viral
infection, i.e., type I interferons (not shown). Data from our
laboratory also suggest that DV infection induces functional
maturity in DC (manuscript in preparation).
Evidence for in vivo infection of skin DC in dengue vaccine
recipient A 26-y-old Asian female volunteer in a phase I
clinical trial of a tetravalent live, attenuated dengue vaccine
developed a maculopapular rash 12 d after the subcutaneous
injection of the vaccine. A skin punch biopsy of the rash was
taken from the lower extremity. Figure 5(a±d) shows stained skin
biopsies from the rash. Figure 5(a) is a formalin-®xed para®n-
Figure 3. Flow cytometry application of the ADE assay using immune serum. (a) ADE assay comparing K562 cells (positive control cells) and
immature DC after exposure to DV that had been incubated with various dilutions of immune serum. Abscissa indicates intensity infection as
determined by binding of 2H2-FITC (structural protein) and ordinate is the side scatter (SSC) in each dot plot. (b) Fc receptor expression on immature
DC and K562 cells as determined by binding of speci®c MoAb of each receptor and analyzed using ¯ow cytometry. Graphs show the mean percentage
of cells staining positive for the respective Fc receptor of at least three independent experiments (mean 6 SD).
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embedded biopsy stained with hematoxylin and eosin, revealing a
mild super®cial, dermal, perivascular lymphocytic in®ltrate.
Figure 5(b), a serial section of part (a), stained with anti-CD1a
(a Langerhans' cell marker), delineates enlarged bodies and
extended processes of epidermal Langerhans' cells. Figure 5(c)
and (d) are frozen sections. Figure 5(c) is stained for DV envelope
glycoprotein (2H2) in red and Fig 5(d) demonstrates double
staining of both DV antigens (red) and CD1a expression on
Langerhans' cells (blue).
DISCUSSION
We have reviewed the clinical aspects of dengue infection, skin
manifestations, and complications, and emphasized the enhanced
pathogenicity of dengue under certain conditions. DHF/DSS, once
a geographically restricted phenomenon (South-east Asia), is now
reported in the Americas and considered an emerging infectious
disease. Certain conditions need to exist for complicated dengue
infections to occur within a population. These conditions include
the need for the vector (Aedes aegyptii, now widespread in the
tropics and in the south-eastern parts of the U.S.A.) and multiple
circulating serotypes of dengue, allowing for sequential infections.
These criteria are now present in many areas of the tropics and may
explain the increasing impact of dengue disease in spite of
heightened surveillance and global strategies.
The in vivo evidence for ADE to explain DHF/DSS pathogenesis
is compelling and gaining momentum, but still remains an area of
controversy. The interested reader is referred to several excellent
reviews of dengue and ADE (Halstead, 1970; Burke et al, 1988;
Morens, 1994). The corollary of ADE, higher viremia in more
severe dengue infections, has been published recently in a
prospective trial in 168 Thai children with acute dengue infection
(Vaughn et al, 2000). In addition to higher virus titres correlating
with more severe disease, two other factors emerged from that
study. First, those patients with DEN-2 infection experienced more
severe disease than those infected with other serotypes. Second,
more than 80% of the children studied experienced a secondary DV
infection that was also associated with more severe disease. The
association of DEN-2 with severe disease has been born out in
many trials with the particular sequence of DEN-x followed by
Figure 4. TNF-a production by dengue-
exposed DC induces DC maturation. (a)
TNF-a protein detected (ELISA) in culture
supernatants 24 h after DV exposure. Virus
concentration indicated on abscissa and TNF-a in
pg per ml plotted on ordinate. (b) CD83
expression on DC exposed to DEN-2 (black line
on histogram) in the presence of 20 mg per ml
anti-TNF-a antibody or IgG control antibody.
Green line is the mock infected (media alone)
DC.
Figure 5. Infection of skin DC in DV vaccine recipient. (a±d) Skin
biopsies from the lower extremity rash area. (a) Hematoxylin and eosin
staining of formalin ®xed, paraf®n-embedded sections showing a mild,
super®cial, dermal perivascular lymphocytic in®ltrate. (b) CD1a
immunohistochemistry staining of a serial section of that in (a) showing
enlarged cell bodies and processes of intraepithelial Langerhans' cells. (c)
Frozen section stained with 2H2, a MoAb speci®c for envelope
glycoprotein, shows two red cells containing DV glycoprotein. (d)
Double labeling of frozen section using a Langerhans' cell marker, CD1a
(blue) and a DV antigen, 2H2 (red). Scale bars: (a) 10 mm, (b) 15 mm, (c,
d) 5 mm.
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DEN-2 being a distinct predisposing risk factor for severe disease
(Morens, 1994).
We have extended our previous work (Wu et al, 2000) that
showed that immature skin DC can be infected by DV and may be
early targets for DV infection. Our data suggest that the FcRII that
is involved in ADE is apparently not involved in the entry of DV
into DC, or at least is not susceptible to immune enhancement
phenomenon. DC do not manifest ADE, whereas the K562 cells
display much higher levels of infectivity at subneutralizing antibody
concentrations. Interestingly, both the immature DC and the K562
cells expressed moderate levels of FcRII. In fact, a greater
percentage of the immature DC expressed FcRII and at greater
intensity when compared with K562 cells. It is recognized,
however, that although DC may bear Fc receptors, there may be
variability in the expression of subunits of these receptors and/or
variability in receptor function (de la Salle et al, 1997). Our results
are in agreement with earlier work supporting the idea of two
different entry mechanisms for DV, one being Fc-dependent and
the other being Fc-independent (Daughaday et al, 1981).
In addition, we have extended our previous work by proposing a
mechanism for the dengue-induced maturation of DC exposed to
the virus. We and colleagues (Ho et al, 2001) have shown that
exposure of immature DC to DV induces TNF-a production.
Here we show TNF-a-blocking experiments to demonstrate the
inhibition of maturation (as de®ned by CD83 expression) in the
presence of anti-TNF antibody that blocks soluble and membrane-
bound TNF.
Our data extend previous reports in primates and mice that
suggested that DV could replicate in the skin and supported the
concept that Langerhans cells/DC migrated from the skin (i.e., the
site of antigenic challenge) and traveled to the draining lymph node
by demonstration of antigen-labeled veiled cells in the lymphatics
of sensitized animals (Taweechaisupapong et al, 1996a,b). The
following scenario seems possible: the Langerhans cell is infected
shortly after the bite of the mosquito and local replication of DV
ensues. Some of these infected Langerhans cells/DC migrate to the
draining lymph node where the virus can spread or be transferred to
other cells in the context of a dengue-bearing DC. Once the virus
has been ampli®ed, and if the appropriate level of subneutralizing
antibody is present or generated in the serum, the virus gains access
to the monocyte/macrophage cellular compartment and DHF/DSS
may develop. The triggering of an in¯ammatory cytokine cascade,
including the in vivo induction of TNF- a (Green et al, 1999), may
play a role in dengue pathogenesis. Both monocytes/macrophages
and DC produce TNF-a. One report indicates that whereas DV-
infected monocytes produce TNF-a in the presence of enhancing
antibodies, more IL-1b is induced (Shaio et al, 1995) ± both
cytokines being early elements of the cytokine cascade. Other
factors involved in severe disease are hemorrhagic events; some
recent work implicates the virus itself as being able to activate
plasminogen and subsequent ®brinolytic processes, supporting virus
virulence mechanisms at work (Monroy and Ruiz, 2000).
Currently there is no licensed dengue vaccine. Historically, we
have had our best successes against viral pathogens using live
attenuated vaccines. The complexities of DV, the four distinct
serotypes, and the likelihood that immune enhancement is playing
a role in disease pathogenesis pose unique vaccine development
challenges. Current vaccine design employs tetravalent candidates
with the hopes of eliciting a protective immune response against all
four serotypes.
The understanding of the cellular targets of dengue infection and
the downstream consequences of DV infection at the cellular and
molecular level, and of the viral virulence factors in the context of
dengue pathogenesis, is of fundamental importance for the
advancement of safe and effective strategies. Continued active
research focused on understanding these phenomenon may advance
vaccine development as it continues into the twenty-®rst century.
We thank Douglas Walsh, Armed Forces Research Institute Medical Sciences,
Bangkok, Thailand for the courtesy of the photograph in Fig 1.
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